Search
Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDarunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigationalDarunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesOxtriphylline
go.drugbank.com/drugs/DB01303ApprovedOxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously ...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInsulin detemir
go.drugbank.com/drugs/DB01307ApprovedInvestigationalInsulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously ...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersKava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersHexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates